Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

December 18, 2013 updated by: AstraZeneca

A 24-week, Multicentre, Randomised, Double-blind,Age-stratified, Placebo Controlled Phase III Study With an 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin 10 mg Once Daily in Patients With T2DM and Cardiovascular Disease, Who Exhibit Inadequate Glycaemic Control on Usual Care

This study is carried out to assess whether dapagliflozin improves glycemic control, decreases fasting plasma glucose levels, body weight and blood pressure when added to patient's existing medications and how it compares with their usual treatment without added dapagliflozin. Safety data will be collected and analysed to confirm that treatment with dapagliflozin is safe and well tolerated in patients who have diabetes and cardiovascular disease

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

964

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Argentina
      • Cordoba, Argentina
        • Research Site
      • Salta, Argentina
        • Research Site
      • Santa Fe, Argentina
        • Research Site
    • Caba
      • Buenos Aires, Caba, Argentina
        • Research Site
    • Santa Fe
      • Rosario, Santa Fe, Argentina
        • Research Site
  • Australia
      • Herston, Australia
        • Research Site
    • New South Wales
      • Blacktown, New South Wales, Australia
        • Research Site
      • Broadmeadow, New South Wales, Australia
        • Research Site
      • Hornsby, New South Wales, Australia
        • Research Site
      • Wollongong, New South Wales, Australia
        • Research Site
    • Queensland
      • Carina Heights, Queensland, Australia
        • Research Site
      • Kippa-ring, Queensland, Australia
        • Research Site
    • South Australia
      • Adelaide, South Australia, Australia
        • Research Site
      • Bedford Park, South Australia, Australia
        • Research Site
      • Keswick, South Australia, Australia
        • Research Site
    • Victoria
      • Box Hill, Victoria, Australia
        • Research Site
      • Heidelberg, Victoria, Australia
        • Research Site
  • Austria
      • Wien, Austria
        • Research Site
  • Bulgaria
      • Blagoevgrad, Bulgaria
        • Research Site
      • Pernik, Bulgaria
        • Research Site
      • Pleven, Bulgaria
        • Research Site
      • Russe, Bulgaria
        • Research Site
      • Sevlievo, Bulgaria
        • Research Site
      • Sofia, Bulgaria
        • Research Site
      • Stara Zagora, Bulgaria
        • Research Site
      • Varna, Bulgaria
        • Research Site
  • Canada
      • Quebec, Canada
        • Research Site
    • Alberta
      • Calgary, Alberta, Canada
        • Research Site
      • Edmonton, Alberta, Canada
        • Research Site
    • New Brunswick
      • Moncton, New Brunswick, Canada
        • Research Site
    • Newfoundland and Labrador
      • Bay Roberts, Newfoundland and Labrador, Canada
        • Research Site
    • Nova Scotia
      • Halifax, Nova Scotia, Canada
        • Research Site
    • Ontario
      • Etobicoke, Ontario, Canada
        • Research Site
      • Ottawa, Ontario, Canada
        • Research Site
      • Scarborough, Ontario, Canada
        • Research Site
      • Thornhill, Ontario, Canada
        • Research Site
      • Toronto, Ontario, Canada
        • Research Site
    • Quebec
      • Mirabel, Quebec, Canada
        • Research Site
  • Chile
    • Region Metropolitana
      • Santiago, Region Metropolitana, Chile
        • Research Site
  • Germany
      • Damme, Germany
        • Research Site
      • Dortmund, Germany
        • Research Site
      • Homburg, Germany
        • Research Site
      • Munster, Germany
        • Research Site
      • Wangen, Germany
        • Research Site
  • Hungary
      • Ajka, Hungary
        • Research Site
      • Balatonfured, Hungary
        • Research Site
      • Budapest, Hungary
        • Research Site
      • Esztergom, Hungary
        • Research Site
      • Gyor, Hungary
        • Research Site
      • Komarom, Hungary
        • Research Site
      • Mosonmagyarovar, Hungary
        • Research Site
      • TAT, Hungary
        • Research Site
      • Veszprem, Hungary
        • Research Site
  • Poland
      • Bialystok, Poland
        • Research Site
      • Chrzanow, Poland
        • Research Site
      • Gdansk, Poland
        • Research Site
      • Grodzisk Mazowiecki, Poland
        • Research Site
      • Ilawa, Poland
        • Research Site
      • Kielce, Poland
        • Research Site
      • Krakow, Poland
        • Research Site
      • Leczna, Poland
        • Research Site
      • Leczyca, Poland
        • Research Site
      • Lodz, Poland
        • Research Site
      • Lublin, Poland
        • Research Site
      • Mragowo, Poland
        • Research Site
      • Nowy Sacz, Poland
        • Research Site
      • Plock, Poland
        • Research Site
      • Poznan, Poland
        • Research Site
      • Ruda Slaska, Poland
        • Research Site
      • Skierniewice, Poland
        • Research Site
      • Sopot, Poland
        • Research Site
      • Tarnow, Poland
        • Research Site
      • Torun, Poland
        • Research Site
      • Warszawa, Poland
        • Research Site
      • Wroclaw, Poland
        • Research Site
      • Zabrze, Poland
        • Research Site
      • Zgierz, Poland
        • Research Site
      • Zielona Gora, Poland
        • Research Site
  • United States
    • Alabama
      • Birmingham, Alabama, United States
        • Research Site
    • Arizona
      • Scottsdale, Arizona, United States
        • Research Site
    • California
      • Anaheim, California, United States
        • Research Site
      • Bell Gardens, California, United States
        • Research Site
      • Chino, California, United States
        • Research Site
      • Chula Vista, California, United States
        • Research Site
      • Huntington Beach, California, United States
        • Research Site
      • Los Angeles, California, United States
        • Research Site
      • Mission Hills, California, United States
        • Research Site
      • Redondo Beach, California, United States
        • Research Site
      • Riverside, California, United States
        • Research Site
      • Sacramento, California, United States
        • Research Site
      • San Diego, California, United States
        • Research Site
      • Torrance, California, United States
        • Research Site
    • Florida
      • Aventura, Florida, United States
        • Research Site
      • Boca Raton, Florida, United States
        • Research Site
      • Bradenton, Florida, United States
        • Research Site
      • Brooksville, Florida, United States
        • Research Site
      • Clearwater, Florida, United States
        • Research Site
      • Dania, Florida, United States
        • Research Site
      • Delray Beach, Florida, United States
        • Research Site
      • New Smyrna Beach, Florida, United States
        • Research Site
      • Orlando, Florida, United States
        • Research Site
    • Illinois
      • Springfield, Illinois, United States
        • Research Site
    • Indiana
      • Avon, Indiana, United States
        • Research Site
      • Franklin, Indiana, United States
        • Research Site
      • Greenfield, Indiana, United States
        • Research Site
      • Muncie, Indiana, United States
        • Research Site
    • Iowa
      • Waterloo, Iowa, United States
        • Research Site
    • Kansas
      • Topeka, Kansas, United States
        • Research Site
    • Kentucky
      • Paducah, Kentucky, United States
        • Research Site
    • Louisiana
      • Alexandria, Louisiana, United States
        • Research Site
    • Maryland
      • Rockville, Maryland, United States
        • Research Site
    • Michigan
      • Kalamazoo, Michigan, United States
        • Research Site
      • Livonia, Michigan, United States
        • Research Site
    • Montana
      • Billings, Montana, United States
        • Research Site
    • New Jersey
      • Berlin, New Jersey, United States
        • Research Site
      • Brick, New Jersey, United States
        • Research Site
    • North Carolina
      • Asheboro, North Carolina, United States
        • Research Site
    • North Dakota
      • Fargo, North Dakota, United States
        • Research Site
    • Ohio
      • Cincinnati, Ohio, United States
        • Research Site
    • Oklahoma
      • Oklahoma City, Oklahoma, United States
        • Research Site
    • Pennsylvania
      • Altoona, Pennsylvania, United States
        • Research Site
      • Erie, Pennsylvania, United States
        • Research Site
      • Holland, Pennsylvania, United States
        • Research Site
      • Lancaster, Pennsylvania, United States
        • Research Site
      • Media, Pennsylvania, United States
        • Research Site
      • Philadelphia, Pennsylvania, United States
        • Research Site
    • Texas
      • Austin, Texas, United States
        • Research Site
      • Corpus Christi, Texas, United States
        • Research Site
      • Dallas, Texas, United States
        • Research Site
      • Irving, Texas, United States
        • Research Site
      • Richardson, Texas, United States
        • Research Site
      • San Antonio, Texas, United States
        • Research Site
      • Sugarland, Texas, United States
        • Research Site
    • Virginia
      • Alexandria, Virginia, United States
        • Research Site
      • Manassas, Virginia, United States
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

45 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Type 2 diabetes mellitus.
  • Cardiovascular disease
  • Uninterrupted anti-diabetic treatment for at least 8 weeks before enrolment

Exclusion Criteria:

  • Patients with type 1 diabetes or diabetes insipidus
  • Patients with 3 or more oral anti-hyperglycaemic drugs with or without insulin and/or poorly controlled diabetes
  • Any clinically significant illness, which would compromise the patient's safety and their participation in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: QUADRUPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: 1
dapagliflozin 10 mg tablet
Drug: Dapagliflozin
10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
PLACEBO_COMPARATOR: 2
matching placebo tablet
Drug: Placebo
matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adjusted Mean Change in HbA1c Levels
Time Frame: Baseline to Week 24
To compare the glycemic efficacy of dapagliflozin 10 mg versus placebo when added to usual care in type 2 diabetes patients with cardiovascular disease, measured as the mean change in HbA1c from baseline to week 24.
Baseline to Week 24
Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit
Time Frame: Baseline to Week 24
To compare the clinical benefit of dapagliflozin 10 mg versus placebo when added to usual care in type 2 diabetes patients with cardiovascular disease at week 24, measured as the proportion of responders for a 3-item endpoint of clinical benefit, defined as an absolute drop of 0.5% or more from baseline HbA1c, and a relative drop of 3% or more from baseline for total body weight, and an absolute drop of 3 mmHg or more from baseline in seated systolic blood pressure.
Baseline to Week 24

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adjusted Mean Percent Change in Body Weight
Time Frame: Baseline to Week 24
To compare the mean percent change in body weight from baseline to week 24 between dapagliflozin 10 mg versus placebo.
Baseline to Week 24
Proportion of Participants With a Reduction From Baseline of 5% or More in Body Weight in Participants With Baseline BMI ≥27 kg/m²
Time Frame: Baseline to Week 24
To compare the proportion of participants with BMI baseline ≥27 kg/m2 with a reduction from baseline of 5% or more in body weight with dapagliflozin 10 mg versus placebo from baseline to week 24. Least Squares Mean represents the percent of participants adjusted for baseline body weight and age stratum.
Baseline to Week 24
Adjusted Mean Change in Systolic Blood Pressure at Week 8 (LOCF)
Time Frame: Baseline to Week 8
To compare the mean change in seated systolic blood pressure from baseline to week 8 between dapagliflozin 10 mg versus placebo.
Baseline to Week 8
Adjusted Mean Change in Seated Systolic Blood Pressure at Week 24 (LOCF)
Time Frame: Baseline to Week 24
To compare the mean change in seated systolic blood pressure from baseline to week 24 between dapagliflozin 10 mg versus placebo.
Baseline to Week 24
Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) at Week 8 (LOCF) in Participants With Baseline SBP>=130 mmHg
Time Frame: Baseline to Week 8
To compare the mean change in seated systolic blood pressure (SBP) in participants with baseline seated SBP ≥130 mmHg achieved with dapagliflozin versus placebo from baseline to week 8.
Baseline to Week 8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AstraZeneca

Collaborators

Bristol-Myers Squibb

Investigators

  • Principal Investigator: Dr. Lawrence A Leiter, MD, Division of Endocrinology & Metabolism, St Michael's Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2010

Primary Completion (ACTUAL)

May 1, 2011

Study Completion (ACTUAL)

December 1, 2012

Study Registration Dates

First Submitted

January 5, 2010

First Submitted That Met QC Criteria

January 5, 2010

First Posted (ESTIMATE)

January 6, 2010

Study Record Updates

Last Update Posted (ESTIMATE)

February 17, 2014

Last Update Submitted That Met QC Criteria

December 18, 2013

Last Verified

December 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • D1690C00019

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Disease

Clinical Trials on Dapagliflozin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe